-
1Academic Journal
Authors: A. V. Yagoda, P. V. Koroy, T. R. Dudov, А. В. Ягода, П. В. Корой, Т. Р. Дудов
Source: The Russian Archives of Internal Medicine; Том 15, № 3 (2025); 216-225 ; Архивъ внутренней медицины; Том 15, № 3 (2025); 216-225 ; 2411-6564 ; 2226-6704
Subject Terms: международное нормализованное отношение, histological activity, matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinases-1, γ-glutamyl transpep tidase, international normalized ratio, гистологическая активность, матриксная металлопротеиназа-9, тканевой ингибитор матриксных металлопротеиназ-1, γ-глютамилтранспептидаза
File Description: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/2007/1416; https://www.medarhive.ru/jour/article/view/2007/1424; Moon A.M., Singal A.G., Tapper E.B. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin. Gastroenterol. Hepatol. 2020; 18: 2650-2666. doi:10.1016/j.cgh.2019.07.060; Devarbhavi H., Asrani S.K., Arab J.P. et al. Global burden of liver disease: 2023 update. J. Hepatol. 2023; 79 (2): 516-537. doi:10.1016/j.jhep.2023.03.017; Jeng W., Papatheodoridis G., Lok A.S. F. Hepatitis B. Lancet. 2023; 401 (10381): 1039-1052. doi:10.1016/s0140-6736(22)01468-4; Stockdale A.J., Kreuels B., Henrion M.Y. R. et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J. Hepatol. 2020; 73: 523-532. doi:10.1016/j.jhep.2020.04.008; Petagine L., Zariwala M.G., Patel V.B. Alcoholic liver disease: current insights into cellular mechanisms. World J. Biol. Chem. 2021; 12 (5): 87-103. doi:10.4331/wjbc.v12.i5.87.; EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis — 2021 update. J. Hepatol. 2021; 75 (3): 659-689. doi:10.1016/j.jhep.2021.05.025; Pokorska-Śpiewak M., Kowalik-Mikołajewska B., Aniszewska M. et al. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest — comparison with histopathological assessment. Clin. Exp. Hepatol. 2017; 3 (4): 187-193. doi:10.5114/ceh.2017.7107919; Bril F., McPhaul M.J., Caulfield M.P. et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 dibetes mellitus. J. Investig. Med. 2019; 67: 303-311. doi:10.1136/jim-2018-000864; Geervliet E., Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells. 2020; 9: 1212. doi:10.3390/cells9051212; Chen J., Xu W., Chen Y. et al. Matrix metalloproteinase 9 facilitates hepatitis B virus replication through binding with type I interferon (IFN) receptor 1 to repress IFN/JAK/STAT signaling. J. Virol. 2017; 91 (8): e01824-16. doi:10.1128/JVI.01824-16; Wang X., Maretti-Mira A.C., Wang L. et al. Liver-selective MMP- 9 inhibition in the rat eliminates ischemia-reperfusion injury and accelerates liver regeneration. Hepatology. 2019; 69: 314-328. doi:10.1002/hep.30169; Ягода А.В., Корой П.В., Дудов Т.Р. Матриксные металлопротеиназы и морфологическая картина при хронических заболеваниях печени. Экспериментальная и клиническая гастроэнтерология. 2023; 218 (10): 153-159. doi:10.31146/1682-8658-ecg-218-10-153-159; Behairy O.G., El-Bakry M.M., Mansour A.I. et al. Matrix metalloproteinase-1 as a non-invasive biomarker to assess liver fibrosis in children with chronic liver disease. Egypt. Liver J. 2021; 11: 80. doi:10.1186/s43066-021-00148-x; Lam S., Singh R., Dillman J.R. et al. Serum matrix metalloproteinase 7 is a diagnostic biomarker of biliary injury and fibrosis in pediatric autoimmune liver disease. Hepatology Communications. 2020; 4 (11): 1680-1693. doi:10.1002/hep4.1589; Zhan J., Wang J., Zhang Z. et al. Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase. Virulence. 2023; 14 (1). 2268497. doi:10.1080/21505594.2023.2268497; Chen S., Huang H. Clinical non-invasive model to predict liver inflammation in chronic hepatitis B with alanine aminotransferase ≤ 2 upper limit of normal. Front. Med. 2021; 8: 661725. doi:10.3389/fmed.2021.66172529; Jiang S., Wang J., Zhang Z. et al. Development and validation of a nomogram to predict significant liver inflammation in patients with chronic hepatitis B. Infect. Drug Resist. 2023; 16: 5065-5075. doi:10.2147/IDR.S417007; Li X., Xing Y., Zhou D. et al. A non-invasive model for predicting liver inflammation in chronic hepatitis B patients with normal serum alanine aminotransferase levels. Front. Med. 2021; 8: 688091. doi:10.3389/fmed.2021.688091; Xu W.S., Qiu X.M., Ou Q.S. et al. Red blood cell distribution width levels correlate with liver fibrosis and inflammation: a noninvasive serum marker panel to predict the severity of fibrosis and inflammation in patients with hepatitis B. Medicine. 2015; 94 (10): e612. doi:10.1097/MD.0000000000000612; Wang H., Xu H., Qu L. et al. Red blood cell distribution width and globulin, noninvasive indicators of fibrosis and inflammation in chronic hepatitis patients. Eur. J. Gastroenterol. Hepatol. 2016; 28: 997-1002. doi:10.1097/MEG.0000000000000662; Yao M., Wang L., Wang J. et al. Diagnostic value of serum Golgi protein 73 for liver inflammation in patients with autoimmune hepatitis and primary biliary cholangitis. Dis. Markers. 2022; 2022: 4253566. doi:10.1155/2022/4253566; Yao K., Wang J., Wang L. et al. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA. J. Med. Virol. 2022; 94 (2): 659-666. doi:10.1002/jmv.27327; Liu J., Wang J., Yan X. et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis. Hepatol. Commun. 2022; 6 (4): 855- 866. doi:10.1002/hep4.1859; Mussbacher M., Brunnthaler L., Panhuber A. et al. Till death do us part — the multifaceted role of platelets in liver diseases. Int. J. Mol. Sci. 2021; 22: 3113. doi:10.3390/ijms22063113; Negrin L.L., Carlin G.L., Ristl R. et al. Serum levels of matrix metalloproteinases 1, 2, and 7, and their tissue inhibitors 1, 2, 3, and 4 in polytraumatized patients: time trajectories, correlations, and their ability to predict mortality. PLoS One. 2024; 19 (3): e0300258. doi:10.1371/journal.pone.0300258; Shan L., Wang F., Zhai D J. et al. Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis. Biomed. Pharmacother. 2023; 161: 114472. doi:10.1016/j.biopha.2023.114472; Latronico T., Mascia C., Pati I. et al. Liver fibrosis in HCV monoinfected and HIV/HCV coinfected patients: dysregulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) and effect of HCV protease inhibitors. Int. J. Mol. Sci. 2016; 17: 455. doi:10.3390/ijms17040455; Tsomidis I., Notas G., Xidakis C. et al. Enzymes of fibrosis in chronic liver disease. Biomedicines. 2022; 10 (12): 3179. doi:10.3390/biomedicines10123179; Ando W., Yokomori H., Tsutsui N. et al. Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. Clin. Mol. Hepatol. 2018; 24 (1): 61-76. doi:10.3350/cmh.2017.0030; Martinez-Castillo M., Hernandez-Barragan A., Flores-Vasconcelos I. et al. Production and activity of matrix metalloproteinases during liver fibrosis progression of chronic hepatitis C patients. World J. Hepatol. 2021; 13 (2): 218-232. doi:10.4254/wjh.v13.i2.218; Zdanowicz K., Kowalczuk-Kryston M., Olanski W. et al. Increase in serum MMP-9 and TIMP-1 concentrations during alcohol intoxication in adolescents — a preliminary study. Biomolecules. 2022; 12: 710. doi:10.3390/biom12050710; Li Y., Liu H., Xu L. Expression of MMP-9 in different degrees of chronic hepatitis B and its correlation with inflammation. Exp. Ther. Med. 2018; 16: 4136-4140. doi:10.3892/etm.2018.6673; Yu D., Li Y., Xu Y. et al. Dysregulated matrix metalloproteinases and tissue inhibitors of metalloproteinase in residual splenic tissue after subtotal splenectomy due to portal hypertension. Int. J. Clin. Exp. Pathol. 2017; 10 (2): 1273-1282.; Sufleţel R.T., Melincovici C.S., Gheban B.A. et al. Hepatic stellate cells — from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology. Rom. J. Morphol. Embryol. 2020; 61 (3): 615-642. doi:10.47162/RJME.61.3.01; Andrade T.G., Xavier L.C. D., Souza F.F. et al. Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease — a survey in a university hospital in Brazil. Arch. Endocrinol. Metab. 2022; 66 (6): 823-830. doi:10.20945/2359-3997000000514; Кравченко Ю.А., Корой П.В. «Воспалительный индекс» и гистологическая картина при неалкогольной жировой болезни печени. Медицинский вестник Северного Кавказа. 2023; 18 (4): 409-411. doi:10.14300/mnnc.2023.18097; Ягода А.В., Корой П.В., Сляднев С.А. Положительная корреляция уровня молекул суперсемейства иммуноглобулинов ICAM-1, VCAM-1, PECAM-1 с показателями индекса фиброза при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2017; 138 (2): 45-51.; https://www.medarhive.ru/jour/article/view/2007